Rocket Pharmaceuticals, Inc.RCKTNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P10
Near historical low
vs 5Y Ago
-0.5x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -19.98% |
| Q3 2025 | -26.65% |
| Q2 2025 | -12.04% |
| Q1 2025 | 12.27% |
| Q4 2024 | -6.54% |
| Q3 2024 | 1.99% |
| Q2 2024 | 24.44% |
| Q1 2024 | -0.81% |
| Q4 2023 | 15.87% |
| Q3 2023 | 6.97% |
| Q2 2023 | 9.80% |
| Q1 2023 | -16.92% |
| Q4 2022 | 26.08% |
| Q3 2022 | 17.51% |
| Q2 2022 | 9.21% |
| Q1 2022 | -3.30% |
| Q4 2021 | 21.42% |
| Q3 2021 | 5.33% |
| Q2 2021 | -12.78% |
| Q1 2021 | 33.07% |
| Q4 2020 | 43.12% |
| Q3 2020 | -16.08% |
| Q2 2020 | -4.68% |
| Q1 2020 | 43.81% |
| Q4 2019 | 14.88% |
| Q3 2019 | -1.52% |
| Q2 2019 | 15.63% |
| Q1 2019 | 32.91% |
| Q4 2018 | 26.32% |
| Q3 2018 | -44.68% |
| Q2 2018 | -52.67% |
| Q1 2018 | 144.14% |
| Q4 2017 | -8.91% |
| Q3 2017 | 74.51% |
| Q2 2017 | -22.20% |
| Q1 2017 | 4.48% |
| Q4 2016 | 18.82% |
| Q3 2016 | -0.17% |
| Q2 2016 | -8.21% |
| Q1 2016 | 9.22% |